lem-3 Antibody

What is LEM-3/ANKLE1 and what is its fundamental role in cellular processes?

LEM-3 (Ankle1 in humans) functions as a specialized DNA nuclease that processes DNA bridges physically linking chromosomes before cell division. It localizes specifically to the midbody, the structure where abscission occurs at the end of cytokinesis. This protein plays a crucial role in maintaining genomic integrity by resolving chromatin bridges that arise from multiple sources including incomplete DNA replication, unresolved recombination intermediates, or perturbance of chromosome structure .

Failure to properly resolve these DNA connections can lead to serious genomic instability, including chromosome severing, failed cell division, aneuploidy, and polyploidization. These events represent fundamental threats to genomic integrity and cellular function .

How is LEM-3/ANKLE1 structurally characterized?

LEM-3/ANKLE1 is characterized by its distinctive domain architecture that includes:

• A LEM (LAP2, emerin, MAN1) domain, which typically mediates interactions with chromatin and nuclear envelope proteins

• Ankyrin repeat domains that likely facilitate protein-protein interactions

• A GIY-YIG nuclease domain that confers its DNA processing activity

The protein can be recognized by antibodies raised against specific immunogenic regions. For instance, some antibodies target a 15-amino acid synthetic peptide near the carboxy terminus (CAGWPPARRRRLGVHL), while others recognize longer sequences within the protein structure .

What is the evolutionary relationship between C. elegans LEM-3 and human ANKLE1?

ANKLE1 (Ankyrin repeat and LEM domain containing 1) is the human orthologue of C. elegans LEM-3. The functional conservation of this protein across species highlights its evolutionary importance in maintaining genome integrity. Research using C. elegans as a model organism has provided critical insights into the function of this protein, with direct implications for understanding the role of ANKLE1 in human cells. Notably, this evolutionary conservation extends to potential roles in disease contexts, with ANKLE1 being suspected to play a role in human breast cancer development or progression .

What types of LEM-3/ANKLE1 antibodies are available for research applications?

Researchers have access to several types of LEM-3/ANKLE1 antibodies with varying properties as summarized in the table below:

These antibodies provide researchers with options based on their specific experimental needs, including different host species, detection applications, and target species reactivity .

What validation methods should be used to confirm LEM-3/ANKLE1 antibody specificity?

For rigorous research applications, validation of LEM-3/ANKLE1 antibody specificity is essential and should include:

• Protein array validation: Some commercial antibodies have been verified on protein arrays containing the target protein plus hundreds of non-specific proteins to ensure binding specificity .

• Positive and negative control tissues/cells: Using samples with known expression levels of LEM-3/ANKLE1, including knockout/knockdown controls when available.

• Western blot analysis: To confirm the antibody recognizes a protein of the expected molecular weight.

• Cross-reactivity assessment: Testing against related proteins, particularly other LEM domain-containing proteins, to ensure specificity.

• Immunofluorescence localization validation: Confirming the antibody detects the protein at its expected subcellular location (midbody during cytokinesis).

What are the optimal conditions for storing LEM-3/ANKLE1 antibodies to maintain their activity?

Proper storage of LEM-3/ANKLE1 antibodies is critical for maintaining their activity and specificity over time:

• For short-term storage, keep antibodies at 4°C (refrigerated).

• For long-term storage, aliquot the antibody and store at -20°C.

• Avoid repeated freeze-thaw cycles as they can lead to protein denaturation and loss of antibody activity.

• For conjugated antibodies (e.g., DyLight 405-conjugated), store at 4°C in the dark to prevent photobleaching of the fluorophore .

Many commercial antibodies are supplied in stabilizing buffers containing glycerol (e.g., PBS, pH 7.2, containing 40% glycerol with 0.02% sodium azide), which helps prevent freezing at -20°C and maintains antibody stability .

What are the optimal protocols for detecting LEM-3/ANKLE1 using immunohistochemistry?

For effective immunohistochemical detection of LEM-3/ANKLE1 in paraffin-embedded tissues:

• Sample preparation: Use standard fixation protocols with 10% neutral buffered formalin, followed by paraffin embedding and sectioning (4-6 μm thickness).

• Antigen retrieval: This critical step typically requires heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Antibody dilution: For rabbit polyclonal antibodies, a dilution range of 1:1000 to 1:2500 is recommended for optimal signal-to-noise ratio .

• Detection system: Use an appropriate secondary antibody system compatible with the primary antibody host species, coupled with a visualization method such as DAB (3,3'-diaminobenzidine).

• Controls: Include positive and negative controls in each experiment to validate staining specificity.

The exact protocol may need optimization based on the specific antibody used and the tissue type being examined.

How should researchers design experiments to study LEM-3/ANKLE1 localization at the midbody?

To effectively study LEM-3/ANKLE1 localization at the midbody during cell division:

• Cell synchronization: Methods like double thymidine block or nocodazole treatment can enrich for cells at specific cell cycle stages.

• Co-immunostaining: Use antibodies against established midbody markers (e.g., Aurora B, MKLP1) alongside LEM-3/ANKLE1 antibodies to confirm midbody localization.

• Time-course experiments: Sample cells at different time points during mitosis and cytokinesis to capture the dynamic localization pattern of LEM-3/ANKLE1.

• High-resolution microscopy: Confocal or super-resolution microscopy is recommended for precise localization studies, as the midbody is a relatively small structure.

• DNA bridge induction: Use treatments that induce chromatin bridges (e.g., replication inhibitors like aphidicolin) to observe increased LEM-3/ANKLE1 accumulation at the midbody .

What are the recommended approaches for using LEM-3/ANKLE1 antibodies in Western blotting applications?

For optimal Western blot detection of LEM-3/ANKLE1:

• Sample preparation: Extract proteins using RIPA or NP-40 based lysis buffers containing protease inhibitors.

• Gel electrophoresis: Use 8-10% SDS-PAGE gels for effective resolution of the protein (molecular weight consideration).

• Transfer conditions: Standard semi-dry or wet transfer to PVDF or nitrocellulose membranes.

• Blocking: 5% non-fat milk or BSA in TBST, depending on the specific antibody requirements.

• Primary antibody incubation: For unconjugated rabbit polyclonal antibodies, a dilution of approximately 1:500 is typically recommended .

• Detection system: HRP-conjugated secondary antibodies with enhanced chemiluminescence (ECL) detection.

• Expected band size: Confirm detection at the expected molecular weight for LEM-3/ANKLE1 (approximately 60-65 kDa, depending on the species).

How does LEM-3/ANKLE1 resolve chromatin bridges during cell division?

LEM-3/ANKLE1 employs a sophisticated mechanism to resolve chromatin bridges during cell division:

• Midbody-tethered activity: Unlike most DNA processing enzymes that function in the nucleus, LEM-3 specifically localizes to the midbody during cytokinesis, where it acts as a "last chance" nuclease to resolve persistent DNA bridges before abscission.

• Bridge sensing mechanism: LEM-3 accumulation is increased and prolonged specifically when chromatin bridges are trapped at the cleavage plane, suggesting an adaptive response to the presence of DNA bridges .

• Processing diverse DNA structures: LEM-3 has the capability to process various types of DNA structures that can form bridges, including:

  • Incompletely replicated DNA

  • Unresolved recombination intermediates

  • Structurally perturbed chromosomes

• Nuclease activity: The GIY-YIG nuclease domain of LEM-3/ANKLE1 likely generates DNA breaks that allow physical separation of the DNA bridges, permitting completion of cytokinesis.

This localized DNA processing represents a unique genome maintenance mechanism that acts specifically at the final stages of cell division.

What is the functional relationship between LEM-3/ANKLE1 and the BRC-1/BRCA1 pathway?

LEM-3/ANKLE1 exhibits a significant functional relationship with the BRC-1/BRCA1 homologous recombination pathway:

• Cooperative action: Studies in C. elegans have demonstrated that LEM-3 acts cooperatively with BRC-1 (the C. elegans ortholog of human BRCA1) to maintain genome integrity .

• Complementary mechanisms: While BRC-1/BRCA1 primarily functions in homologous recombination-mediated DNA repair during S and G2 phases, LEM-3/ANKLE1 acts later during cytokinesis to resolve any persistent DNA bridges that escaped earlier repair mechanisms.

• Synthetic phenotypes: Genetic studies suggest that disruption of both pathways simultaneously leads to more severe genomic instability than disruption of either pathway alone, indicating they work in parallel or complementary pathways.

• Cancer relevance: This functional relationship provides a potential molecular basis for the suspected role of ANKLE1 in human breast cancer, particularly given the well-established role of BRCA1 mutations in breast cancer predisposition .

This cooperation between early acting (BRC-1/BRCA1) and late acting (LEM-3/ANKLE1) genome maintenance factors ensures comprehensive protection against chromosome segregation errors.

How is LEM-3/ANKLE1 activity regulated by AIR-2/Aurora B kinase?

LEM-3/ANKLE1 activity is precisely regulated by AIR-2/Aurora B kinase through several mechanisms:

• Phosphorylation-dependent control: AIR-2/Aurora B kinase likely phosphorylates LEM-3/ANKLE1 directly, regulating its activity and localization to the midbody.

• Temporal regulation: Aurora B kinase activity peaks during mitosis and cytokinesis, coinciding with when LEM-3/ANKLE1 function is required.

• Spatial control: Aurora B localizes to the midbody during cytokinesis, where it can regulate LEM-3/ANKLE1 in a spatially controlled manner.

• Integration with abscission timing: The Aurora B-mediated abscission checkpoint, which delays final cytoplasmic separation when chromatin bridges are present, likely coordinates with LEM-3/ANKLE1 activity to ensure DNA bridges are resolved before abscission proceeds .

This regulation ensures that LEM-3/ANKLE1 nuclease activity is properly controlled to prevent inappropriate DNA cutting while ensuring it functions when and where needed during cell division.

What are common challenges in LEM-3/ANKLE1 antibody-based experiments and how can they be overcome?

Researchers working with LEM-3/ANKLE1 antibodies may encounter several challenges:

• Low signal intensity:

  • Solution: Optimize antibody concentration, increase incubation time, use more sensitive detection systems, or try signal amplification methods.

  • Prevention: Ensure proper antigen retrieval for IHC applications and confirm sample preparation preserves the epitope.

• High background:

  • Solution: Increase blocking time/concentration, optimize antibody dilution, increase washing steps.

  • Prevention: Use highly purified antibodies and ensure proper blocking of non-specific binding sites.

• Cross-reactivity:

  • Solution: Validate antibody specificity using knockout/knockdown controls or peptide competition assays.

  • Prevention: Select antibodies that have been validated for specificity against related proteins.

• Inconsistent midbody staining:

  • Solution: Synchronize cells to enrich for cytokinesis stages, use co-staining with established midbody markers.

  • Prevention: Carefully time experiments to capture the relatively brief cytokinesis stage.

• Variability between experiments:

  • Solution: Standardize protocols, use consistent lot numbers of antibodies when possible.

  • Prevention: Include positive controls in each experiment to normalize results.

How can researchers quantify LEM-3/ANKLE1 activity in various experimental settings?

Quantifying LEM-3/ANKLE1 activity requires multiple complementary approaches:

• Fluorescence intensity measurements:

  • Measure the intensity of immunofluorescence staining at the midbody using software like ImageJ/FIJI.

  • Normalize to a co-stained midbody marker to account for midbody size variations.

• Bridge resolution assays:

  • Induce DNA bridges using replication inhibitors or other treatments.

  • Quantify the frequency of unresolved bridges in control versus LEM-3/ANKLE1-depleted cells.

  • Compare the timing of bridge resolution in various experimental conditions.

• Chromatin immunoprecipitation (ChIP):

  • Use LEM-3/ANKLE1 antibodies to immunoprecipitate the protein along with associated DNA.

  • Analyze the bound DNA to identify sequences preferentially processed by LEM-3/ANKLE1.

• In vitro nuclease assays:

  • Immunoprecipitate LEM-3/ANKLE1 using validated antibodies.

  • Test the nuclease activity of the immunoprecipitated protein on various DNA substrates.

• Live-cell imaging:

  • Use fluorescently tagged LEM-3/ANKLE1 to monitor its dynamics and correlation with bridge resolution in real-time.

What controls should be included in LEM-3/ANKLE1 antibody-based experiments?

Rigorous experimental design for LEM-3/ANKLE1 studies should include the following controls:

• Positive controls:

  • Cell lines or tissues known to express LEM-3/ANKLE1

  • Recombinant LEM-3/ANKLE1 protein (for Western blot)

  • Cells enriched for cytokinesis/midbody stages (for immunofluorescence)

• Negative controls:

  • LEM-3/ANKLE1 knockout/knockdown cells or tissues

  • Primary antibody omission control

  • Isotype control (matched to the primary antibody)

  • Pre-immune serum (for polyclonal antibodies)

• Specificity controls:

  • Peptide competition/blocking with the immunizing peptide

  • Multiple antibodies targeting different epitopes of LEM-3/ANKLE1

  • Antibodies against related proteins to check for cross-reactivity

• Technical controls:

  • Loading controls for Western blot (housekeeping proteins)

  • Nuclear/cytoplasmic/midbody markers for localization studies

  • Cell cycle markers to identify specific cell cycle stages

• Functional controls:

  • AIR-2/Aurora B kinase inhibition to assess regulation

  • DNA bridge induction to confirm LEM-3/ANKLE1 function

  • BRC-1/BRCA1 depletion to test cooperative functions

Incorporating these controls ensures the reliability and reproducibility of results in LEM-3/ANKLE1 research.